Recist versus Choi Criteria Response Assesment in Patients with Advanced Pancreatic Neuroendocrine Tumor (PNET) Treated with Sunitinib Abstract #1247

Introduction: Classically, the response assessment to systemic treatment is based on RECIST. In PNET treated with antiangiogenic targeted therapy as sunitinib there is no good correlation between response rate and progression free survival (PFS). Choi criteria might be an alternative to RECIST to evaluate the effect of sunitinib in patients with advanced PNET
Aim(s): To explore Choi as an appropriate response assessment method in PNET treated with sunitinib.
Materials and methods: 17 patients with advanced PNET treated with sunitinib were evaluated by Computed Tomography (CT) using CHOI and RECIST, every 3 months. According to Choi criteria, partial response (PR) was defined as ≥10% decrease in size or ≥15% decrease in attenuation.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula Jiménez-Fonseca
Keywords: sunitinib, PNET, Choi, RECIST

To read results and conclusion, please login ...

Further abstracts you may be interested in

No result